Candel Therapeutics (CADL) Non-Current Debt (2021 - 2025)

Candel Therapeutics' Non-Current Debt history runs 5 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• In Q4 2025, Non-Current Debt rose 15.86% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (up 15.86% YoY), while the FY2025 annual figure was $1.0 million, up 15.86% from the prior year.
• Non-Current Debt came in at $1.0 million for Q4 2025 at Candel Therapeutics, up from $904000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $20.2 million in Q4 2022 to a low of $560000.0 in Q4 2021.
• A 5-year average of $7.8 million and a median of $1.0 million in 2025 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 3507.5% in 2022 and tumbled 95.15% in 2024, its largest moves.
• Candel Therapeutics' Non-Current Debt stood at $560000.0 in 2021, then surged by 3507.5% to $20.2 million in 2022, then slumped by 42.42% to $11.6 million in 2023, then sank by 92.52% to $870000.0 in 2024, then rose by 15.86% to $1.0 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $1.0 million, $904000.0, and $870000.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.

Peer Comparison